Overview

Antidepressant Treatment of Mexican-Americans: UCLA Pharmacogenetics and Pharmacogenomics Research Group

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
0
Participant gender:
All
Summary
Our goal is to study pharmacogenetics in Mexican-Americans, using depression treatments as a proof of the concept that pharmacogenetic approaches can be used to optimize treatment strategies for common and complex disorders in this population.
Phase:
Phase 2
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
National Institute of General Medical Sciences (NIGMS)
Treatments:
Desipramine
Fluoxetine
Criteria
Inclusion Criteria: 1) At least 3 out of 4 grandparents born in Mexico [12]. 2) DSM-IV
diagnosis of current, unipolar major depressive episode [13]. 3) 21-Item Hamilton
Depression Rating Scale (HAM-D) [14] score of 18 or greater with item #1 (depressed mood)
rated 2 or greater. 4) Age between 18-70 years.

-

Exclusion Criteria: 1) Any axis I disorder other than major depressive disorder (e.g.
dementia, psychotic illness, bipolar disorder, adjustment disorder) or primary anxiety
disorders. 2) Active medical illnesses that could be related to the ongoing depression
(e.g. untreated hypothyroidism, recent myocardial infarction or cerebrovascular accident
within the past six months, uncontrolled hypertension or diabetes). 3) Current suicidal
ideation with a plan and strong intent, or recent serious suicide attempt. 4) Pregnant or
lactating women, or women of childbearing age not using contraception. 5) History of
electroconvulsive therapy in the last six months. 6) Current use of medications with
central nervous system activity which interfere with EEG activity (e.g. benzodiazepines) or
any other antidepressant treatment within the 2 weeks prior to enrollment. 7) History of
poor response to therapeutic treatment with desipramine or fluoxetine. 8) Illicit drug use
and/or alcohol abuse in the last three months. 9) Current enrollment in counseling or
psychotherapies.

-